Nazarzadeh Behnam, Ghazanfari Saeedeh Sadat, Karimi Farzaneh, Moezibady Seyed Ali, Salmani Fatemeh, Dastjerdi Kazem, Mohammadi Hamidreza
Department of Medical Biotechnology, Faculty of Medicine Birjand University of Medical Sciences Birjand Iran.
Mashhad University of Medical Sciences Mashhad Branch Islamic Azad University Mashhad Iran.
Health Sci Rep. 2025 Jan 12;8(1):e70284. doi: 10.1002/hsr2.70284. eCollection 2025 Jan.
Mounting evidence have implicated that rs1801131 and rs1801133, located in the Methylenetetrahydrofolate reductase (MTHFR) gene, may emerge as novel biomarkers for coronary artery disease (CAD). The Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score is also an appropriate predictor for revascularization strategy in patients with complex CAD. The aim of this study is to investigate the correlation between rs1801131 and rs1801133 with the severity of coronary lesions in patients with ST‑Elevation Myocardial Infarction (STEMI) and Non‑ST‑Elevation Myocardial Infarction (NSTEMI) based on the SYNTAX score.
This retrospective cross-sectional study included 96 patients diagnosed with STEMI and NSTEMI from Razi University Hospital between April and September 2019. Ninety-six patients were diagnosed with STEMI ( = 43) and NSTEMI ( = 53) were recruited from South Khorasan, Iran. The angiographical characteristics of CAD were defined by the SYNTAX score. Genomic DNA was isolated from peripheral blood and genotyped for rs1801131 and rs1801133 using the TaqMan real-time PCR method.
The results of the one-way analysis of variance indicated that there is no association between rs1801131 and rs1801133 with the severity of coronary lesions in patients with STEMI ( = 0.44) and NSTEMI ( = 0.91). However, the two-way analysis of variance comparison and post-hoc test demonstrated that rs1801133 in the presence of rs1801131 is correlated with the SYNTAX score in NSTEMI ( = 0.03) and total patients ( = 0.03).
In conclusion, our study reveals a significant association between the MTHFR polymorphism rs1801133 and CAD severity, particularly in NSTEMI patients. While rs1801131 showed no correlation, rs1801133 may serve as a valuable genetic biomarker for assessing CAD severity. Further research with larger populations is needed to confirm these findings.
越来越多的证据表明，位于亚甲基四氢叶酸还原酶（MTHFR）基因中的rs1801131和rs1801133可能成为冠状动脉疾病（CAD）的新型生物标志物。紫杉醇药物洗脱支架与心脏外科手术协同作用（SYNTAX）评分也是复杂CAD患者血运重建策略的合适预测指标。本研究的目的是基于SYNTAX评分，探讨rs1801131和rs1801133与ST段抬高型心肌梗死（STEMI）和非ST段抬高型心肌梗死（NSTEMI）患者冠状动脉病变严重程度之间的相关性。
这项回顾性横断面研究纳入了2019年4月至9月期间在拉齐大学医院诊断为STEMI和NSTEMI的96例患者。96例患者中，43例诊断为STEMI，53例诊断为NSTEMI，均来自伊朗南呼罗珊省。CAD的血管造影特征由SYNTAX评分定义。从外周血中分离基因组DNA，并使用TaqMan实时PCR方法对rs1801131和rs1801133进行基因分型。
单因素方差分析结果表明，rs1801131和rs1801133与STEMI患者（P = 0.44）和NSTEMI患者（P = 0.91）的冠状动脉病变严重程度之间无关联。然而，双因素方差分析比较和事后检验表明，在存在rs1801131的情况下，rs1801133与NSTEMI患者（P = 0.03）和所有患者（P = 0.03）的SYNTAX评分相关。
总之，我们的研究揭示了MTHFR基因多态性rs1801133与CAD严重程度之间存在显著关联，尤其是在NSTEMI患者中。虽然rs1801131未显示出相关性，但rs1801133可能作为评估CAD严重程度的有价值的遗传生物标志物。需要进一步开展更大规模人群的研究来证实这些发现。
